DelveInsight’s “Biliary Atresia Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Key Takeaways from the Biliary Atresia Market Research Report

• The increase in Biliary Atresia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Biliary Atresia Market is anticipated to witness growth at a considerable CAGR.
• The leading Biliary Atresia Companies working in the market include Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others.
• Promising Biliary Atresia Therapies in the various stages of development include BYLVAY, LIVMARLI, and others.
• March 2024:- Mirum Pharmaceuticals Inc.- Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy. A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
• March 2024: Albireo- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (BOLD-EXT). This is a Phase 3, multi-center, open-label extension study to evaluate the long-term efficacy and safety of odevixibat in patients with Biliary Atresia (BA). Patients who completed treatment in the A4250-011 BOLD study and meet eligibility criteria for Study A4250-016 (BOLD-EXT) can participate. The duration of the treatment period is 104 weeks, followed by a 4-week Safety Follow-up Period. Patients who wish to continue receiving odevixibat after 104 weeks can remain on treatment in the optional extension period (OEP).

 

Discover which therapies are expected to grab the Biliary Atresia Market Share @ Biliary Atresia Market Outlook

 

Biliary Atresia Overview

Biliary atresia is a rare liver disease that affects newborns. It occurs when the bile ducts, which carry bile from the liver to the gallbladder and small intestine, are either blocked or absent. This blockage prevents bile from flowing out of the liver, leading to a buildup of bile within the liver. Over time, this buildup damages the liver cells and can result in liver failure. Biliary atresia is typically diagnosed within the first few weeks or months of life and requires prompt medical intervention, often in the form of surgery to restore bile flow or a liver transplant. It is a serious condition that requires lifelong management and monitoring.

 

Biliary Atresia Epidemiology Insights

The Biliary Atresia epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology [segmented as Incident cases of Biliary Atresia, Type-specific Incident Cases of Biliary Atresia, Gender-specific Incident Cases of Biliary Atresia, and Treatable Cases of Biliary Atresia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Download the report to understand which factors are driving Biliary Atresia Epidemiology trends @ Biliary Atresia Epidemiological Insights

 

Biliary Atresia Drugs Market

The Biliary Atresia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Biliary Atresia signaling in Biliary Atresia are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Biliary Atresia Treatment Market Landscape

The Biliary Atresia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Biliary Atresia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To learn more about Biliary Atresia treatment guidelines, visit @ Biliary Atresia Treatment Market Landscape

 

Biliary Atresia Market Outlook

The report’s outlook on the Biliary Atresia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Biliary Atresia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Biliary Atresia drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Biliary Atresia market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Biliary Atresia Drugs Uptake

The drug chapter of the Biliary Atresia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Biliary Atresia.

 

Major Biliary Atresia Companies

Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others.

 

Learn more about the FDA-approved drugs for Biliary Atresia @ Drugs for Biliary Atresia Treatment

 

Scope of the Biliary Atresia Market Report

• Coverage- 7MM
• Biliary Atresia Companies- Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others.
• Biliary Atresia Therapies- BYLVAY, LIVMARLI, and others.
• Biliary Atresia Market Dynamics: Biliary Atresia Market Drivers and Barriers
• Biliary Atresia Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Biliary Atresia Drugs in development @ Biliary Atresia Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Biliary Atresia Executive Summary

3. Competitive Intelligence Analysis for Biliary Atresia

4. Biliary Atresia: Market Overview at a Glance

5. Biliary Atresia: Disease Background and Overview

6. Patient Journey

7. Biliary Atresia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Biliary Atresia Unmet Needs

10. Key Endpoints of Biliary Atresia Treatment

11. Biliary Atresia Marketed Products

12. Biliary Atresia Emerging Therapies

13. Biliary Atresia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Biliary Atresia Market Outlook

16. Biliary Atresia Market Access and Reimbursement Overview

17. Biliary Atresia KOL Views

18. Biliary Atresia Market Drivers

19. Biliary Atresia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/